Study List
StudyViewSet
GET /api/v1/_studies/?format=api
{ "current_page": 1, "last_page": 34, "next_page_url": "https://pk-db.com/api/v1/_studies/?format=api&page=2", "prev_page_url": null, "data": { "count": 674, "data": [ { "sid": "3113968", "name": "Ullrich1987", "date": "2023-01-04", "reference": "3113968", "creator": "jbrandhorst", "curators": [ { "rating": 0.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.5, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {} ] }, { "characteristica": [ {}, {}, {}, {} ] }, { "characteristica": [ {}, {}, {}, {} ] } ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Ullrich1987_TabA.tsv" } ] }, "interventionset": { "interventions": [ {} ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Ullrich1987_Tab2.tsv", "image": "https://pk-db.com/media/data/Ullrich1987_Tab2.png" }, { "source": "https://pk-db.com/media/data/.Ullrich1987_Fig2.tsv", "image": "https://pk-db.com/media/data/Ullrich1987_Fig2.png" } ] }, "dataset": {}, "files": [ "https://pk-db.com/media/data/Ullrich1987.xlsx", "https://pk-db.com/media/data/.Ullrich1987_Fig2.tsv", "https://pk-db.com/media/data/Ullrich1987_Fig2.png", "https://pk-db.com/media/data/Ullrich1987_Tab2.png", "https://pk-db.com/media/data/Ullrich1987.pdf", "https://pk-db.com/media/data/.Ullrich1987_TabA.tsv", "https://pk-db.com/media/data/.Ullrich1987_Tab2.tsv" ] }, { "sid": "PKDB00183", "name": "Paintaud1998", "date": "2019-09-26", "reference": "9516037", "creator": "jbrandhorst", "curators": [ { "rating": 2.7, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "descriptions": [ "The pharmacokinetics of paracetamol was studied on two occasions in 15 healthy volunteers without Helicobacter pylori antibodies.", "Thirty-five healthy subjects were pre-included and tested for the absence of Helicobacter pylori antibodies by means of an ELISA (Institut Pasteur, Paris): 15 (14 males and 1 female) had negative serology and therefore participated in the study.", "The mean (range) age was 37 (20–51) years, body weight 77 (60–100) kg and height 177 (168–196) cm. All were found to be healthy by routine clinical examination and laboratory tests, including measurement of blood glucose. They had no medical history, except for an appendectomy in two subjects and the surgical cure of an inguinal hernia in one subject.", "The ultra-sound examination of the abdomen was normal in all subjects except for one who had a single kidney.", "None of the subjects was a smoker and none had taken drugs for at least 1 week before the study." ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {}, {}, {}, {}, {} ], "comments": [ [ "jbrandhorst", "subjects infected with this bacteria (Helicobacter pylori) were not included in the study" ], [ "jbrandhorst", "one subject had a single kidney" ] ] } ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Paintaud1998_TabA.tsv", "characteristica": [ {} ] } ] }, "interventionset": { "descriptions": [ "A 1-g dose of paracetamol was given as a solution together with a standardised semi-solid meal and the subjects stayed in the supine position.", "Paracetamol pharmacokinetics was studied on two occasions separated by a 1-week interval (studies were performed on the same day of the week for each volunteer), except for subject 9, for whom the interval was 10 days. After overnight fasting, the subjects were given 1 g paracetamol (Eeralgan, eervescent tablets, UPSA, France) dissolved in 100 ml water at 0800 hours. The drug was taken together with a standardised semi-solid meal, consisting of a mixture of two doses of vanilla flavour Nutricre´ mal (Sodie´ tal, Saint-Malo, France), 10 g sunflower oil and 28 g maltose dextrin, corresponding to 18% proteins, 31% lipids and 52% carbohydrates, for a total of 504 kcal and a volume of 280 ml. Another 100-ml glass of water was given just after the meal and also 2 h later; a non-standardised lunch was served in the research unit 4 h after dosing. Since the absorption of paracetamol is altered by posture and activity [7], the subjects stayed in the supine position, on the right side, for the first 2 h and only modest activity was allowed for the next 4 h." ], "interventions": [ {}, {}, { "comments": [ [ "jbrandhorst", "mixture of two doses of vanilla ̄flavour Nutricremal (Sodietal, Saint-Malo, France), 10 g sunflower oil and 28 g maltose dextrin, corresponding to 18% proteins, 31% lipids and 52% carbohydrates, for a total of 504 kcal and a volume of 280 ml. " ] ] } ] }, "outputset": { "comments": [ [ "jbrandhorst", "It is not clear what values in parentheses represent in Tab1 (clear CV_B and CV_W digitised but not uploaded)" ] ], "outputs": [ { "source": "https://pk-db.com/media/data/.Paintaud1998_Tab1.tsv", "image": "https://pk-db.com/media/data/Paintaud1998_Tab1.png" }, { "source": "https://pk-db.com/media/data/.Paintaud1998_Fig1A.tsv", "image": "https://pk-db.com/media/data/Paintaud1998_Fig1.png" }, { "source": "https://pk-db.com/media/data/.Paintaud1998_Fig1B.tsv", "image": "https://pk-db.com/media/data/Paintaud1998_Fig1B.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "subject2_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject3_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject8_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject6_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject12_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject15_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject10_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject4_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject14_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject5_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject12_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject13_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject9_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject4_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject14_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject7_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject3_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject1_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject15_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject5_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject1_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject13_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject10_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject7_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject2_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject8_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject9_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject11_paracetamol1000mg_po(first),semi-solid meal" }, { "name": "subject11_paracetamol1000mg_po(second),semi-solid meal" }, { "name": "subject6_paracetamol1000mg_po(second),semi-solid meal" } ] } ] }, "files": [ "https://pk-db.com/media/data/.Paintaud1998_Fig1B.tsv", "https://pk-db.com/media/data/Paintaud1998.pdf", "https://pk-db.com/media/data/.Paintaud1998_Fig1A.tsv", "https://pk-db.com/media/data/Paintaud1998.xlsx", "https://pk-db.com/media/data/Paintaud1998_Fig1B.png", "https://pk-db.com/media/data/.Paintaud1998_TabA.tsv", "https://pk-db.com/media/data/Paintaud1998_Fig1.png", "https://pk-db.com/media/data/Paintaud1998_Tab1.png", "https://pk-db.com/media/data/.Paintaud1998_Tab1.tsv" ] }, { "sid": "Sommers1985", "name": "Sommers1985", "date": "2023-01-04", "reference": "4018818", "creator": "jbrandhorst", "curators": [ { "rating": 2.5, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {}, {} ] }, { "source": "https://pk-db.com/media/data/.Sommers1985_TabA.tsv", "characteristica": [ {}, {}, {} ] } ] }, "interventionset": { "interventions": [ {}, {} ], "comments": [ [ "jbrandhorst", "After an overnight fast each subject received 600 mg (two 300 mg capsules) of antipyrine and 1500 mg (three 500 mg tablets) of paracetamol, followed by a glass of drinking water. No food or drink was permitted for a further 2 h." ] ] }, "outputset": { "descriptions": [ "Salivary concentrations of paracetamol and urinary amounts of the glucuronide and sulphate metabolites eliminated over 22 h were determined by HPLC." ], "outputs": [ { "source": "https://pk-db.com/media/data/.Sommers1985_Tab2.tsv", "image": "https://pk-db.com/media/data/Sommers1985_Tab2.png" } ] }, "dataset": {}, "files": [ "https://pk-db.com/media/data/.Sommers1985_Tab2.tsv", "https://pk-db.com/media/data/.Sommers1985_TabA.tsv", "https://pk-db.com/media/data/Sommers1985.xlsx.ods", "https://pk-db.com/media/data/Sommers1985.pdf", "https://pk-db.com/media/data/Sommers1985.xlsx", "https://pk-db.com/media/data/Sommers1985_Tab2.png" ] }, { "sid": "PKDB00027", "name": "Critchley2005", "date": "2019-05-07", "reference": "15811172", "creator": "mkoenig", "curators": [ { "rating": 0.0, "first_name": "Jan", "last_name": "Grzegorzewski", "pk": "580a2907-f59a-4929-a56b-b4d980b6ed3e" }, { "rating": 3.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Dimitra", "last_name": "Eleftheriadou", "pk": "5e82cfed-c8c5-439e-a466-be08e6cc2138" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "descriptions": [ "Eleven Chinese and nine Caucasian healthy local volunteers were recruited. The study was approved by the Chinese University Clinical Research Ethics Committee. All subjects abstained from taking paracetamol-containing and other drugs for 2 weeks prior to the study. Following an overnight fast, an oral dose of paracetamol syrup 20 mg/kg (Panadol, Sterling-Winthrop, New York, NY, USA) was administered with water (100 mL). Subjects then remained sedentary for 2 h.", "Twenty healthy Chinese (n = 11) and Caucasian (n = 9) subjects, aged 21–44 years, 11 male and nine female, were given oral paracetamol syrup 20 mg/kg, following an overnight fast.", "Demographics in Table 1." ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {} ] }, { "characteristica": [ {}, {}, {}, {}, {}, {} ] }, { "characteristica": [ {}, {}, {}, {}, {}, {} ] } ] }, "individualset": {}, "interventionset": { "descriptions": [ "An oral dose of paracetamol syrup 20 mg/kg (Panadol, Sterling-Winthrop, New York, NY, USA) was administered with water (100 mL)", "Blood samples were taken into heparinized tubes from an intravenous canula inserted in the forearm before and at 0.25, 0.5, 0.75, 1.0, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 24 h following paracetamol administration. Urine was saved for 0–24 h with chloroform as preservative." ], "interventions": [ {} ] }, "outputset": { "comments": [ [ "mkoenig", "urinary recoveries have not been curated from publication" ] ], "outputs": [ { "source": "https://pk-db.com/media/data/.Critchley2005_Tab2.tsv", "image": "https://pk-db.com/media/data/Critchley2005_Tab2.png" }, { "source": "https://pk-db.com/media/data/.Critchley2005_Fig1.tsv", "image": "https://pk-db.com/media/data/Critchley2005_Fig1.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "Caucasians_paracetamol sulfate" }, { "name": "Chinese_paracetamol cysteine" }, { "name": "Chinese_paracetamol" }, { "name": "Caucasians_paracetamol" }, { "name": "Chinese_paracetamol glucuronide" }, { "name": "Caucasians_paracetamol glucuronide" }, { "name": "Chinese_paracetamol sulfate" }, { "name": "Caucasians_paracetamol cysteine" } ] } ] }, "files": [ "https://pk-db.com/media/data/Critchley2005_Tab1.png", "https://pk-db.com/media/data/Critchley2005.pdf", "https://pk-db.com/media/data/.Critchley2005_Fig1old.tsv", "https://pk-db.com/media/data/Critchley2005_Fig1_py.png", "https://pk-db.com/media/data/.Critchley2005_Tab2.tsv", "https://pk-db.com/media/data/Critchley2005_Tab2.png", "https://pk-db.com/media/data/Critchley2005_Fig1.png", "https://pk-db.com/media/data/Critchley2005.xlsx", "https://pk-db.com/media/data/Critchley2005_Tab3.png", "https://pk-db.com/media/data/.Critchley2005_Fig1.tsv" ] }, { "sid": "PKDB00182", "name": "Singla2012", "date": "2019-09-26", "reference": "22524979", "creator": "jbrandhorst", "curators": [ { "rating": 2.7, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {}, {}, {}, {}, {}, {}, {} ], "comments": [ [ "jbrandhorst", "BMI is given in lbs/in^2, values seem to be in kg/m^2" ], [ "jbrandhorst", "All subjects met eligibility criteria with the exception of 2 subjects given a waiver for BMIs of 25.3 and 25.6. Each subject had an unremarkable medical history, was afebrile, and had normal vital signs and physical examinations on clinic admission. One subject was discontinued from study participation and replaced [...] on day 2 after post PO PK assessments were completed; however, his results from day 1 PO dosing were included in the final PK results (Table 1). One subject in the PR group had missing CSF samples and was therefore excluded from the analysis (Table 2)." ] ] } ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Singla2012_TabA.tsv" } ] }, "interventionset": { "descriptions": [ "Healthy male subjects (N = 6) were randomized to receive a single dose of IV (OFIRMEV; Cadence) 1,000 mg (15 minute infusion), PO (2 Tylenol 500 mg caplets; McNeil Consumer Healthcare), or PR acetaminophen (2 Feverall 650 mg suppositories; Actavis) with a 1-day washout period between doses. The 1,300 mg PR concentrations were standardized to 1,000 mg." ], "interventions": [ {} ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Singla2012_Tab1.tsv", "image": "https://pk-db.com/media/data/Singla2012_Tab1.png" }, { "source": "https://pk-db.com/media/data/.Singla2012_Tab2.tsv", "image": "https://pk-db.com/media/data/Singla2012_Tab2.png" }, { "source": "https://pk-db.com/media/data/.Singla2012_Fig4.tsv", "image": "https://pk-db.com/media/data/Singla2012_Fig4.png" }, { "source": "https://pk-db.com/media/data/.Singla2012_Fig5.tsv", "image": "https://pk-db.com/media/data/Singla2012_Fig5.png" }, { "source": "https://pk-db.com/media/data/.Singla2012_Fig6.tsv", "image": "https://pk-db.com/media/data/Singla2012_Fig6.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "Subject 7_plasma_paracetamol1000mg_po" }, { "name": "plasma_paracetamol1000mg_iv" }, { "name": "cerebrospinal fluid_paracetamol1000mg_po" }, { "name": "Subject 6_plasma_paracetamol1000mg_iv" }, { "name": "Subject 5_plasma_paracetamol1000mg_iv" }, { "name": "Subject 3_plasma_paracetamol1000mg_pr" }, { "name": "cerebrospinal fluid_paracetamol1000mg_iv" }, { "name": "Subject 5_plasma_paracetamol1000mg_po" }, { "name": "Subject 7_plasma_paracetamol1000mg_pr" }, { "name": "Subject 4_plasma_paracetamol1000mg_pr" }, { "name": "Subject 3_plasma_paracetamol1000mg_po" }, { "name": "Subject 6_plasma_paracetamol1000mg_pr" }, { "name": "Subject 4_plasma_paracetamol1000mg_iv" }, { "name": "Subject 6_plasma_paracetamol1000mg_po" }, { "name": "Subject 3_plasma_paracetamol1000mg_iv" }, { "name": "cerebrospinal fluid" }, { "name": "Subject 4_plasma_paracetamol1000mg_po" }, { "name": "Subject 7_plasma_paracetamol1000mg_iv" }, { "name": "Subject 1_plasma_paracetamol1000mg_po" }, { "name": "Subject 1_plasma_paracetamol1000mg_iv" }, { "name": "plasma_paracetamol1000mg_po" }, { "name": "Subject 5_plasma_paracetamol1000mg_pr" }, { "name": "Subject 1_plasma_paracetamol1000mg_pr" }, { "name": "plasma" } ] } ] }, "files": [ "https://pk-db.com/media/data/.Singla2012_Fig6.tsv", "https://pk-db.com/media/data/Singla2012_Tab2.png", "https://pk-db.com/media/data/Singla2012_Fig7.png", "https://pk-db.com/media/data/.Singla2012_Fig4.tsv", "https://pk-db.com/media/data/Singla2012_Fig2.png", "https://pk-db.com/media/data/Singla2012_Fig5.png", "https://pk-db.com/media/data/.Singla2012_TabA.tsv", "https://pk-db.com/media/data/Singla2012_Fig4.png", "https://pk-db.com/media/data/Singla2012.xlsx", "https://pk-db.com/media/data/Singla2012_Tab1.png", "https://pk-db.com/media/data/.Singla2012_Tab2.tsv", "https://pk-db.com/media/data/Singla2012_Fig3.png", "https://pk-db.com/media/data/Singla2012_Fig6.png", "https://pk-db.com/media/data/.Singla2012_Fig5.tsv", "https://pk-db.com/media/data/.Singla2012_Tab1.tsv", "https://pk-db.com/media/data/Singla2012.pdf" ], "comments": [ [ "jbrandhorst", "All subjects met eligibility criteria with the exception of 2 subjects given a waiver for BMIs of 25.3 and 25.6." ] ] }, { "sid": "PKDB00024", "name": "Baraka1990", "date": "2019-05-07", "reference": "2306420", "creator": "mkoenig", "curators": [ { "rating": 0.0, "first_name": "Jan", "last_name": "Grzegorzewski", "pk": "580a2907-f59a-4929-a56b-b4d980b6ed3e" }, { "rating": 2.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Dimitra", "last_name": "Eleftheriadou", "pk": "5e82cfed-c8c5-439e-a466-be08e6cc2138" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "descriptions": [ "Ten healthy volunteers were treated for 4 days with 160 mg propranolol HCl and placebo in random order. At the end of each treatment salivary antipyrine kinetics and the plasma kinetics and urinary excretion of paracetamol and its major metabolites were measured following a 1500 mg oral dose." ], "licence": "open", "access": "public", "groupset": { "descriptions": [ "Subjects: Six males and four females, all clinically healthy, aged between 21 and 32 years and weighing from 51 to 85 kg (median 68 kg) participated in the study.", "All were non-smokers, used alcohol in moderation and did not take other drugs, including oral contraceptives." ], "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {}, {}, {}, {}, {} ] } ] }, "individualset": {}, "interventionset": { "descriptions": [ "On day 4 a single oral dose of paracetamol (1500 mg) was administered and the subjects continued to fast for 2 h. Venous blood samples (5 ml) were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 h. A complete urine collection was made for the first 24 h following drug administration.", "On day 5 the subjects received a single oral dose of 600 mg antipyrine. Saliva (2 ml) was obtained at 0, 3, 6, 9, 12 and 24 h." ], "interventions": [ {}, {}, {} ] }, "outputset": { "outputs": [ {}, {}, {}, {}, {}, {}, { "source": "https://pk-db.com/media/data/.Baraka1990_Fig1.tsv", "image": "https://pk-db.com/media/data/Baraka1990_Fig1.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "paracetamol,propanolol" }, { "name": "paracetamol" } ] } ] }, "files": [ "https://pk-db.com/media/data/Baraka1990_Tab1.png", "https://pk-db.com/media/data/Baraka1990.xlsx", "https://pk-db.com/media/data/.Baraka1990_Fig1old.tsv", "https://pk-db.com/media/data/Baraka1990.pdf", "https://pk-db.com/media/data/Baraka1990_Fig1.png", "https://pk-db.com/media/data/.Baraka1990_Fig1.tsv" ] }, { "sid": "PKDB00213", "name": "Lowenthal1976", "date": "2019-10-12", "reference": "1263112", "creator": "jbrandhorst", "curators": [ { "rating": 3.7, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "descriptions": [ "Five surgically anephric patients, five physiologically anephric patients (creatinine clearance < 5 ml/min) and three normal volunteers (members of the medical staff) gave their informed consent and participated in this investigation. The patients were maintained on regular hemodialysis, three times a week, and are described in table 1. They were studied on an interdialysis day" ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {}, {} ] }, { "characteristica": [ {}, {}, {}, {} ], "comments": [ [ "mkoenig", "surgically removed kidneys" ] ] }, { "characteristica": [ {}, {}, {}, {} ], "comments": [ [ "mkoenig", "physiologica kidney impairment" ] ] }, { "characteristica": [ {}, {}, {}, {} ] } ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Lowenthal1976_Tab1.tsv", "characteristica": [ {}, {}, {} ] } ] }, "interventionset": { "interventions": [ {} ], "comments": [ [ "jbrandhorst", "All subjects received a single oral dose of acetaminophen, 1 g per 1.73 m2 of body surface area (Tylenol elixir) in the morning on an empty stomach. Food was permitted after 1 hour." ] ] }, "outputset": { "outputs": [ { "source": "17||16||13", "image": "14||7||21" }, { "source": "https://pk-db.com/media/data/.Lowenthal1976_TabA.tsv" }, { "source": "10||4||20", "image": "12||11||15" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "fig1_apapsul+apapglu_plasma" }, { "name": "fig1_paracetamol_plasma" }, { "name": "fig1_paracetamol_saliva" }, { "name": "fig2_apapsul+apapglu_plasma" }, { "name": "fig2_paracetamol_plasma" }, { "name": "fig2_paracetamol_saliva" }, { "name": "fig3_apapsul+apapglu_plasma" }, { "name": "fig3_paracetamol_plasma" }, { "name": "fig3_paracetamol_saliva" } ] } ] }, "files": [ "https://pk-db.com/media/data/Lowenthal1976.xlsx", "https://pk-db.com/media/data/Lowenthal1976.pdf", "https://pk-db.com/media/data/.Lowenthal1976_Fig4.tsv", "https://pk-db.com/media/data/.Lowenthal1976_Fig2.tsv", "https://pk-db.com/media/data/Lowenthal1976_Fig4.png", "https://pk-db.com/media/data/Lowenthal1976_Tab1.png", "https://pk-db.com/media/data/Lowenthal1976_Tab3.png", "https://pk-db.com/media/data/.Lowenthal1976_Fig5.tsv", "https://pk-db.com/media/data/.Lowenthal1976_Tab1.tsv", "https://pk-db.com/media/data/.Lowenthal1976_Fig1.tsv", "https://pk-db.com/media/data/Lowenthal1976_Fig2.png", "https://pk-db.com/media/data/Lowenthal1976_Fig1.png", "https://pk-db.com/media/data/.Lowenthal1976_Tab4.tsv", "https://pk-db.com/media/data/Lowenthal1976_Tab2.png", "https://pk-db.com/media/data/Lowenthal1976_Fig3.png", "https://pk-db.com/media/data/.Lowenthal1976_Tab3.tsv", "https://pk-db.com/media/data/.Lowenthal1976_Tab2.tsv", "https://pk-db.com/media/data/Lowenthal1976_Fig5.png", "https://pk-db.com/media/data/.Lowenthal1976_TabA.tsv", "https://pk-db.com/media/data/.Lowenthal1976_Fig3.tsv", "https://pk-db.com/media/data/Lowenthal1976_Tab4.png" ] }, { "sid": "PKDB00195", "name": "Clements1984", "date": "2019-09-30", "reference": "6487489", "creator": "mkoenig", "curators": [ { "rating": 0.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 2.5, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "open", "access": "public", "groupset": { "descriptions": [ "5 healthy subjects", "Five healthy male subjects (age 29 to 39 years, mean 33.4 years; weight 66 to 83 kg, mean 72.4 kg) who were taking no other drugs participated in the study." ], "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {} ] } ] }, "interventionset": { "descriptions": [ "Each fasted overnight and was given each dose of intravenous paracetamol (5 or 20 mg/kg) by constant infusion over 2 h using an IMED pump (IMED Corporation, California). Intravenous paracetamol (0.875 and 3.5 mg/ml) was prepared in phosphate buffer (pH 6.0) and sterilised by filtration. On subsequent occasions paracetamol was dissolved in 400 ml of 'Coca Cola' and ingested over 2 h; 50 ml aliquots were taken over successive 15 min periods." ], "interventions": [ {}, {}, {}, {}, { "comments": [ [ "jbrandhorst", "paracetamol was dissolved in 400 ml of 'Coca Cola' and ingested over 2 h; 50 ml aliquots were taken over successive 15 min periods." ] ] } ], "comments": [ [ "jbrandhorst", "On subsequent occasions paracetamol was dissolved in 400 ml of 'Coca Cola' and ingested over 2 h" ], [ "jbrandhorst", "The subjectsremained seated for 2 h and then resumednormal activities. Food, drink and tobacco wereallowed after 4 h. " ], [ "jbrandhorst", "Each of the four studies was separated by at least one week." ] ] }, "outputset": { "comments": [ [ "jbrandhorst", "Tab2: Tabulated values of AUC for the 20 mg/kg dose are the observed values divided by 4.0) (mean ± s.d.)" ] ], "outputs": [ { "source": "https://pk-db.com/media/data/.Clements1984_Tab1.tsv", "image": "https://pk-db.com/media/data/Clements1984_Tab1.png" }, { "source": "https://pk-db.com/media/data/.Clements1984_Tab2.tsv", "image": "https://pk-db.com/media/data/Clements1984_Tab2.png" }, { "source": "https://pk-db.com/media/data/.Clements1984_TabA.tsv" }, { "source": "https://pk-db.com/media/data/.Clements1984_Fig1.tsv", "image": "https://pk-db.com/media/data/Clements1984_Fig1.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "paracetamol_iv_20mg/kg" }, { "name": "paracetamol_iv_5mg/kg" }, { "name": "paracetamol_20mg/kg, coca cola" }, { "name": "paracetamol_5mg/kg, coca cola" } ] } ] }, "files": [ "https://pk-db.com/media/data/.Clements1984_Tab1.tsv", "https://pk-db.com/media/data/Clements1984.xlsx", "https://pk-db.com/media/data/.Clements1984_Fig1.tsv", "https://pk-db.com/media/data/Clements1984_Tab1.png", "https://pk-db.com/media/data/Clements1984_Tab2.png", "https://pk-db.com/media/data/.Clements1984_Tab2.tsv", "https://pk-db.com/media/data/.Clements1984_TabA.tsv", "https://pk-db.com/media/data/Clements1984.pdf", "https://pk-db.com/media/data/Clements1984_Fig1.png" ] }, { "sid": "PKDB00025", "name": "Chan1997", "date": "2019-05-07", "reference": "9248766", "creator": "mkoenig", "curators": [ { "rating": 0.0, "first_name": "Jan", "last_name": "Grzegorzewski", "pk": "580a2907-f59a-4929-a56b-b4d980b6ed3e" }, { "rating": 2.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Dimitra", "last_name": "Eleftheriadou", "pk": "5e82cfed-c8c5-439e-a466-be08e6cc2138" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "descriptions": [ "A single oral dose of paracetamol (20 mg/kg)) was given to 38 Chinese patients with noninsulin-dependent diabetes mellitus (NIDDM) who had either normal renal function or varying degrees of renal impairment, with creatinine clearances ranging from 4 to 123 ml/min/(1.73 m^2)." ], "licence": "closed", "access": "public", "groupset": { "descriptions": [ "Of the 38 patients, 20 were male. Mean age was 58 (11) years (range 34–75 years). The mean duration of diagnosed diabetes was 8.1 (3.9) years. There were no significant differences in age, sex and body mass index between the four groups. Mean fasting plasma glucose was 9.61 (3.47) mmol/l, HbA1c was 8.07 (1.46) (%) and fructosamine was 332 (71) µmol/. Known duration of illness, glycaemic control and serum albumin concentration were similar in all groups. Mean creatinine clearances in the four groups were 106 (92–120), 78 (69–86), 46 (40–51) and 16 (13–20) ml/min, respectively." ], "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {}, {}, {}, {}, {} ] }, { "characteristica": [ {}, {} ] }, { "characteristica": [ {}, {}, {} ] }, { "characteristica": [ {}, {}, {} ] }, { "characteristica": [ {}, {}, {} ] } ] }, "individualset": {}, "interventionset": { "descriptions": [ "Following overnight fasting, an oral dose of paracetamol syrup (Panadol, Sterling-Winthrop) 20 mg/kg was administered with 100 ml water. Patients remained sedentary for 2 h, after which their usual medications and diabetic diet were given. Blood was taken into heparinised tubes before and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 24 and 48 h following paracetamol administration. Urine was saved from 0–4, 4–8, 8–24, and 24–48 h with chloroform as preservative." ], "interventions": [ {} ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Chan1997_Tab1.tsv", "subset": "substance==paracetamol", "image": "https://pk-db.com/media/data/Chan1997_Tab1.png" }, { "source": "https://pk-db.com/media/data/.Chan1997_Tab1.tsv", "subset": "substance==paracetamol", "image": "https://pk-db.com/media/data/Chan1997_Tab1.png" }, { "source": "https://pk-db.com/media/data/.Chan1997_Tab1.tsv", "subset": "substance==paracetamol cysteine", "image": "https://pk-db.com/media/data/Chan1997_Tab1.png" }, { "source": "https://pk-db.com/media/data/.Chan1997_Tab1.tsv", "subset": "substance==paracetamol glucuronide", "image": "https://pk-db.com/media/data/Chan1997_Tab1.png" }, { "source": "https://pk-db.com/media/data/.Chan1997_Tab1.tsv", "subset": "substance==paracetamol sulfate", "image": "https://pk-db.com/media/data/Chan1997_Tab1.png" }, { "source": "https://pk-db.com/media/data/.Chan1997_Fig1.tsv", "image": "https://pk-db.com/media/data/Chan1997_Fig1.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "severe renal impairment_paracetamol sulfate" }, { "name": "normal renal function_paracetamol cysteine" }, { "name": "mild renal impairment_paracetamol glucuronide" }, { "name": "moderate renal impairment_paracetamol cysteine" }, { "name": "mild renal impairment_paracetamol" }, { "name": "normal renal function_paracetamol" }, { "name": "severe renal impairment_paracetamol glucuronide" }, { "name": "moderate renal impairment_paracetamol sulfate" }, { "name": "mild renal impairment_paracetamol sulfate" }, { "name": "severe renal impairment_paracetamol cysteine" }, { "name": "mild renal impairment_paracetamol cysteine" }, { "name": "normal renal function_paracetamol sulfate" }, { "name": "moderate renal impairment_paracetamol" }, { "name": "moderate renal impairment_paracetamol glucuronide" }, { "name": "normal renal function_paracetamol glucuronide" }, { "name": "severe renal impairment_paracetamol" } ] } ] }, "files": [ "https://pk-db.com/media/data/Chan1997_Fig1.png", "https://pk-db.com/media/data/Chan1997_Tab1.png", "https://pk-db.com/media/data/.Chan1997_Fig1.tsv", "https://pk-db.com/media/data/Chan1997.xlsx", "https://pk-db.com/media/data/.Chan1997_Fig1_old.tsv", "https://pk-db.com/media/data/Chan1997.pdf", "https://pk-db.com/media/data/.Chan1997_Tab1.tsv" ] }, { "sid": "PKDB00219", "name": "Nimmo1978", "date": "2019-10-25", "reference": "Nimmo1978", "creator": "jbrandhorst", "curators": [ { "rating": 2.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "descriptions": [ "Eight healthy volunteers with a mean + s.d. age of 29 ± 1.8 years and a mean + s.d. weight of 68.8 + 8.2 kg were studied twice. On one occasion the subjects were ambulant throughout the study and on the other they lay on the left side for 2 h and were then ambulant." ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {} ] } ] }, "interventionset": { "interventions": [ {}, {}, {} ], "comments": [ [ "jbrandhorst", "No food, fluid or tobacco was allowed during the study." ], [ "jbrandhorst", "On one occasion the subjects were ambulant throughout the study and on the other they lay on the left side for 2 h and were then ambulant. On both occasions, after an overnight fast, each subject was given 1.5 g paracetamol as three Panadol tablets with 200 ml water." ] ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Nimmo1978_TabA.tsv" }, { "source": "https://pk-db.com/media/data/.Nimmo1978_Fig1.tsv", "image": "https://pk-db.com/media/data/Nimmo1978_Fig1.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "paracetamol1500mg_po,bed rest" }, { "name": "paracetamol1500mg_po,ambulant" } ] } ] }, "files": [ "https://pk-db.com/media/data/Nimmo1978.xlsx", "https://pk-db.com/media/data/Nimmo1978_Fig1.png", "https://pk-db.com/media/data/.Nimmo1978_TabA.tsv", "https://pk-db.com/media/data/Nimmo1978.pdf", "https://pk-db.com/media/data/.Nimmo1978_Fig1.tsv" ] }, { "sid": "PKDB00218", "name": "Lee1981", "date": "2019-10-25", "reference": "7263926", "creator": "jbrandhorst", "curators": [ { "rating": 3.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "descriptions": [ "The population of morbidly obese individuals consisted of four male patients hospitalized on the Endocrinology Ward of the Veterans Administration Medical Center, Houston, Tex., for the purpose of weight reduction through dietary modification. Each patient was maintained on a diet of less than 1200 calories per day and a constant number of calories and percentage of carbohydrates, protein, and fat for at least three days. None of the patients studied was in any phase of acute or rapid weight loss.", "The control subjects were three volunteer males of normal body weight.", "All patients and subjects gave signed informed consent and had no evidence of hepatic or renal disorder." ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {} ] }, { "characteristica": [ {} ], "comments": [ [ "jbrandhorst", "Each patient was maintained on a diet of less than 1200 calories per day and a constant number of calories and percentage of carbohydrates, protein, and fat for at least three days. None of the patients studied was in any phase of acute or rapid weight loss. " ] ] }, { "characteristica": [ {} ] } ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Lee1981_Tab1.tsv", "characteristica": [ {} ] } ] }, "interventionset": { "descriptions": [ "For either group, acetaminophen was administered orally as two 325-mg tablets (Philips Roxane brand of acetaminophen) with 8 oz. of water after an overnight (8-hour) fast." ], "interventions": [ {} ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Lee1981_Tab2.tsv", "image": "https://pk-db.com/media/data/Lee1981_Tab2.png" }, { "source": "https://pk-db.com/media/data/.Lee1981_Tab3.tsv", "image": "https://pk-db.com/media/data/Lee1981_Tab3.png" }, { "source": "https://pk-db.com/media/data/.Lee1981_Fig2.tsv", "image": "https://pk-db.com/media/data/Lee1981_Fig2.png" } ] }, "dataset": {}, "files": [ "https://pk-db.com/media/data/.Lee1981_TabA.tsv", "https://pk-db.com/media/data/Lee1981_Tab3.png", "https://pk-db.com/media/data/Lee1981_Fig2.png", "https://pk-db.com/media/data/Lee1981.pdf", "https://pk-db.com/media/data/Lee1981_Tab2.png", "https://pk-db.com/media/data/.Lee1981_Tab1.tsv", "https://pk-db.com/media/data/Lee1981.xlsx", "https://pk-db.com/media/data/.Lee1981_Tab3.tsv", "https://pk-db.com/media/data/.Lee1981_Tab2.tsv", "https://pk-db.com/media/data/Lee1981_Tab1.png", "https://pk-db.com/media/data/Lee1981_Fig1.png", "https://pk-db.com/media/data/.Lee1981_Fig2.tsv" ] }, { "sid": "PKDB00200", "name": "Prescott1968", "date": "2019-10-01", "reference": "Prescott1968", "creator": "jbrandhorst", "curators": [ { "rating": 3.1, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "descriptions": [ "17 healthy adult volunteers during 5 day control and treatment periods as described previously [17]. Nine volunteers received phenacetin and 8 received APAP; none had taken any drugs during the preceding 6 weeks." ], "groups": [ { "characteristica": [ {}, {}, {}, {}, {} ] }, { "characteristica": [ {}, {} ] }, { "characteristica": [ {}, {} ] } ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Prescott1968_TabA.tsv", "characteristica": [ {} ] } ] }, "interventionset": { "descriptions": [ "On the first treatment day the fasting volunteers took 900 mg. of phenacetin or APAP in gelatine capsules at 8:30 A.M. (zero time), followed by a further 900 mg at 9:00 A.M." ], "interventions": [ {}, {} ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Prescott1968_Tab2.tsv", "image": "https://pk-db.com/media/data/Prescott1968_Tab2.png" }, { "source": "https://pk-db.com/media/data/.Prescott1968_Tab2A.tsv", "image": "https://pk-db.com/media/data/Prescott1968_Tab2.png" }, { "source": "https://pk-db.com/media/data/.Prescott1968_FigA.tsv" }, { "source": "https://pk-db.com/media/data/.Prescott1968_FigB.tsv" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "CW_apap_900mg_1, apap_900mg_2, induced" }, { "name": "BR_apap_900mg_1, apap_900mg_2, induced" }, { "name": "RB_apap_900mg_1, apap_900mg_2, induced" }, { "name": "DS_apap_900mg_1, apap_900mg_2" }, { "name": "LS_apap_900mg_1, apap_900mg_2" }, { "name": "DS_apap_900mg_1, apap_900mg_2, induced" }, { "name": "BR_apap_900mg_1, apap_900mg_2" }, { "name": "LS_apap_900mg_1, apap_900mg_2, induced" }, { "name": "RB_apap_900mg_1, apap_900mg_2" }, { "name": "MG_apap_900mg_1, apap_900mg_2, induced" }, { "name": "apap_900mg_1, apap_900mg_2, induced" }, { "name": "LP_apap_900mg_1, apap_900mg_2, induced" }, { "name": "JJ_apap_900mg_1, apap_900mg_2, induced" }, { "name": "apap_900mg_1, apap_900mg_2" }, { "name": "CW_apap_900mg_1, apap_900mg_2" }, { "name": "LP_apap_900mg_1, apap_900mg_2" }, { "name": "MG_apap_900mg_1, apap_900mg_2" }, { "name": "JJ_apap_900mg_1, apap_900mg_2" } ] } ] }, "files": [ "https://pk-db.com/media/data/Prescott1968.pdf", "https://pk-db.com/media/data/Prescott1968_Tab1B.png", "https://pk-db.com/media/data/.Prescott1968_Tab2.tsv", "https://pk-db.com/media/data/.Prescott1968_Tab1.tsv", "https://pk-db.com/media/data/Prescott1968.xlsx", "https://pk-db.com/media/data/.Prescott1968_FigB.tsv", "https://pk-db.com/media/data/.Prescott1968_Tab2A.tsv", "https://pk-db.com/media/data/.Prescott1968_FigA.tsv", "https://pk-db.com/media/data/Prescott1968_Tab1A.png", "https://pk-db.com/media/data/.Prescott1968_TabA.tsv", "https://pk-db.com/media/data/Prescott1968_Tab2.png" ], "comments": [ [ "mkoenig", "only paracetamol data digitized, phenacetin data not used" ] ] }, { "sid": "PKDB00123", "name": "Lau1994", "date": "2019-05-14", "reference": "7696381", "creator": "mkoenig", "curators": [ { "rating": 3.0, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Dimitra", "last_name": "Eleftheriadou", "pk": "5e82cfed-c8c5-439e-a466-be08e6cc2138" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "descriptions": [ "The assay method was used for the analysis of plasma and urine samples from 6 normal healthy volunteers (four males, two females, aged 23-53 years) following a therapeutic dose of 20 mg of paracetamol per kilogram body weight (Panadol Syrup 160 mg/5 ml, Winthrop Product Inc., USA). Venous blood samples were taken at 0,0.5,1,1.5,2,3,4,5,6,7,8,9,10,11,12 and 24 h after dosing." ], "groups": [ { "characteristica": [ {}, {}, {}, {}, {} ] } ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Lau1994_Tab7.tsv" } ] }, "interventionset": { "descriptions": [ "Therapeutic dose of 20 mg of paracetamol per kilogram body weight (Panadol Syrup 160 mg/5 ml, Winthrop Product Inc., USA)" ], "interventions": [ {} ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Lau1994_Tab7.tsv", "image": "https://pk-db.com/media/data/Lau1994_Tab7.png" }, { "source": "https://pk-db.com/media/data/.Lau1994_Tab7.tsv", "image": "https://pk-db.com/media/data/Lau1994_Tab7.png" }, { "source": "https://pk-db.com/media/data/.Lau1994_Fig4.tsv", "image": "https://pk-db.com/media/data/Lau1994_Fig4.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "paracetamol glucuronide" }, { "name": "paracetamol sulfate" }, { "name": "paracetamol" }, { "name": "paracetamol cysteine" } ] } ] }, "files": [ "https://pk-db.com/media/data/Lau1994_Tab7.png", "https://pk-db.com/media/data/.Lau1994_Tab7.tsv", "https://pk-db.com/media/data/.Lau1994_Fig4.tsv", "https://pk-db.com/media/data/Lau1994.pdf", "https://pk-db.com/media/data/Lau1994.xlsx", "https://pk-db.com/media/data/.Lau1994_Tab7_group.tsv", "https://pk-db.com/media/data/Lau1994_Fig4.png" ] }, { "sid": "4942784", "name": "Levy1971b", "date": "2023-01-04", "reference": "4942784", "creator": "jbrandhorst", "curators": [ { "rating": 1.0, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.5, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {} ] }, {} ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Levy1971b_TabA.tsv" } ] }, "interventionset": { "interventions": [ {}, {}, {}, {}, {} ], "comments": [ [ "jbrandhorst", "They received oral doses of 1 g. acetaminophen in one test, 1g acetaminophen and salicylic acid (1 g 2 hr. before and 0.5 g. 4 hr. after acetaminophen) in the second test, and a total of 1.5 g. salicylic acid (1 g. initially and 0.5 g. 6 hr. later) in the third test. The drugs were given in aqueous solution (salicylic acid as sodium salicylate) in the morning On an empty stomach. Food was withheld for at least 2hr. " ] ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Levy1971b_Tab2.tsv", "image": "https://pk-db.com/media/data/Levy1971b_Tab2.png" }, { "source": "https://pk-db.com/media/data/.Levy1971b_TabB.tsv" }, { "source": "https://pk-db.com/media/data/.Levy1971b_Fig1.tsv", "image": "https://pk-db.com/media/data/Levy1971b_Fig1.png" }, { "source": "https://pk-db.com/media/data/.Levy1971b_Fig2.tsv", "image": "https://pk-db.com/media/data/Levy1971b_Fig2.png" }, { "source": "https://pk-db.com/media/data/.Levy1971b_Fig3.tsv", "image": "https://pk-db.com/media/data/Levy1971b_Fig3.png" }, { "source": "https://pk-db.com/media/data/.Levy1971b_Fig4.tsv", "image": "https://pk-db.com/media/data/Levy1971b_Fig4.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "fig1_apap" }, { "name": "fig1_apap_sa" }, { "name": "fig2_apap" }, { "name": "fig2_apap_sa" }, { "name": "fig3_apap" }, { "name": "fig3_apap_sa" }, { "name": "fig4_apap_sa_1-salicylate glucuronide" }, { "name": "fig4_apap_sa_salicyluric acid" }, { "name": "fig4_sa_1-salicylate glucuronide" }, { "name": "fig4_sa_salicyluric acid" } ] } ] }, "files": [ "https://pk-db.com/media/data/.Levy1971b_Fig1.tsv", "https://pk-db.com/media/data/.Levy1971b_TabA.tsv", "https://pk-db.com/media/data/.Levy1971b_Fig2.tsv", "https://pk-db.com/media/data/.Levy1971b_Tab2.tsv", "https://pk-db.com/media/data/Levy1971b_Fig4.png", "https://pk-db.com/media/data/.Levy1971b_TabB.tsv", "https://pk-db.com/media/data/.Levy1971b_Fig4.tsv", "https://pk-db.com/media/data/Levy1971b_Tab2.png", "https://pk-db.com/media/data/.Levy1971b_Tab2_group.tsv", "https://pk-db.com/media/data/.Levy1971b_Fig3.tsv", "https://pk-db.com/media/data/Levy1971b_Fig1.png", "https://pk-db.com/media/data/Levy1971b_Fig2.png", "https://pk-db.com/media/data/Levy1971b.pdf", "https://pk-db.com/media/data/Levy1971b_Fig3.png", "https://pk-db.com/media/data/Levy1971b.xlsx" ] }, { "sid": "PKDB00188", "name": "Clements1978", "date": "2019-09-30", "reference": "688732", "creator": "jbrandhorst", "curators": [ { "rating": 2.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "descriptions": [ "Eight healthy male volunteers ingested an aqueous solution containing acetaminophen (20 mg/kg) and a nonabsorbable isotopic marker.", "Gastric emptying and acetaminophen absorption were measured simultaneously in eight adult male volunteers aged 26 to 39 after overnight fast." ], "groups": [ { "characteristica": [ {}, {}, {}, {}, {} ] }, {}, {}, {} ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Clements1978_TabA.tsv" } ] }, "interventionset": { "descriptions": [ "The subjects were also studied after intramuscular injection of meperidine (I50 mg) and pentaZf}cine (60 mg) with and without naloxone (1.2 mg)." ], "interventions": [ {}, {}, {}, {} ], "comments": [ [ "jbrandhorst", "each subject drank orange juice (400 ml) containing acetaminophen (20 mg/kg) in solution together with 113mIn DTPA* (300 J.LCi) as a nonabsorbable isotopic marker for the emptying measurements." ], [ "jbrandhorst", "No food, drink, or tobacco was permitted for 4 hr after acetaminophen, and the subjects remained supine throughout this period. Initially each subject was studied on two occasions at least 7 days apart." ] ] }, "outputset": { "outputs": [ { "source": "264||266||261||259", "image": "273||272||262||268" }, { "source": "https://pk-db.com/media/data/.Clements1978_Tab4.tsv", "image": "https://pk-db.com/media/data/Clements1978_Tab4.png" }, { "source": "https://pk-db.com/media/data/.Clements1978_Fig1.tsv", "image": "https://pk-db.com/media/data/Clements1978_Fig1.png" }, { "source": "267||263||257", "image": "258||254||260" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "pentazocine_naloxone study_paracetamol20mg/kg_po_pentazocine60mg_im_naloxone1.2mg_iv" }, { "name": "all_paracetamol20mg/kg_po" }, { "name": "subject3_paracetamol20mg/kg_po" }, { "name": "subject6" }, { "name": "subject2" }, { "name": "pentazocine_study_paracetamol20mg/kg_po_pentazocine60mg_im" }, { "name": "subject2__20mg/kg" }, { "name": "subject2_paracetamol20mg/kg_po_pentazocine60mg_im_naloxone1.2mg_iv" }, { "name": "meperidine_study_paracetamol20mg/kg_po_meperidine150mg_im" }, { "name": "subject2_paracetamol20mg/kg_po" } ] } ] }, "files": [ "https://pk-db.com/media/data/Clements1978_Fig4.png", "https://pk-db.com/media/data/.Clements1978_TabA.tsv", "https://pk-db.com/media/data/Clements1978_Tab4.png", "https://pk-db.com/media/data/.Clements1978_Fig5.tsv", "https://pk-db.com/media/data/Clements1978_Fig3.png", "https://pk-db.com/media/data/.Clements1978_Tab5.tsv", "https://pk-db.com/media/data/Clements1978_Fig5.png", "https://pk-db.com/media/data/.Clements1978_Tab3.tsv", "https://pk-db.com/media/data/Clements1978_Tab3.png", "https://pk-db.com/media/data/.Clements1978_Fig4.tsv", "https://pk-db.com/media/data/.Clements1978_Tab1.tsv", "https://pk-db.com/media/data/Clements1978.xlsx", "https://pk-db.com/media/data/.Clements1978_Tab2.tsv", "https://pk-db.com/media/data/.Clements1978_Fig3.tsv", "https://pk-db.com/media/data/Clements1978_Tab5.png", "https://pk-db.com/media/data/Clements1978.pdf", "https://pk-db.com/media/data/.Clements1978_Tab4.tsv", "https://pk-db.com/media/data/.Clements1978_Fig1.tsv", "https://pk-db.com/media/data/Clements1978_Tab2.png", "https://pk-db.com/media/data/Clements1978_Tab1.png", "https://pk-db.com/media/data/Clements1978_Fig1.png" ] }, { "sid": "PKDB00193", "name": "Bannwarth2001", "date": "2019-09-30", "reference": "11196522", "creator": "jbrandhorst", "curators": [ { "rating": 0.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "descriptions": [ "polymedicated elderly patients with rheumatic pain", "Twelve inpatients (11 women), aged 89 ± 4 years, weight 59 ± 10 kg, receiving 3 to 8 concomitant medications, entered the study. Their creatinine clearance according to the Cockroft-Gault formula was 42 ± 12 ml/min", "Twelve mobile inpatients (11 women, one man), aged 84 to 95 years (mean ± SD 89 ± 4), weighing 45 to 74 kg (59 ± 10 kg) entered the study.", "Smokers and patients receiving enzyme-inducing drugs as well as patients with unstable or active diseases were excluded. Standard laboratory tests (blood cell count, aminotransferases, serum albumin, and creatinine) were within the accepted reference range for this age group. The mean calculated creatinine clearance (Cockroft-Gault equation14) was 42 ± 12 ml/min (range 29–61 ml/min).", "All were receiving longterm therapy with either 3 (n = 5), 4 (n = 3), or 5 to 8 (n = 4) medications, mainly for cardiovascular disorders (n = 9), mild depression (n = 8), or insomnia (n = 7). Theirtreatment was unchanged throughout the study. Smokers and patients receiving enzyme-inducing drugs as well as patients with unstable or active diseaseswere excluded. Standard laboratory tests (blood cell count, aminotransferases, serum albumin, and creatinine) were within the accepted reference range for this age group." ], "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {}, {}, {}, {}, {}, {}, {} ] } ] }, "interventionset": { "interventions": [ {}, {} ], "comments": [ [ "jbrandhorst", "The patients were given acetaminophen 1 g (2 × 500 mg Dafalgan® capsules) with 150 ml tap water in the morning (8:00 AM) and evening (8:00 PM) of Day 1. Then they received 1 g acetaminophen 3 times daily for 5 consecutive days, followed by a single dose of 1 g on the morning of Day 7. Blood samples were collected before morning dosing and at 0.5, 1, 1.5, 2, 4,6, 8, and 10 h post dose on Days 1 and 7." ] ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Bannwarth2001_Tab1.tsv", "image": "https://pk-db.com/media/data/Bannwarth2001_Tab1.png" }, { "source": "https://pk-db.com/media/data/.Bannwarth2001_Fig1.tsv", "image": "https://pk-db.com/media/data/Bannwarth2001_Fig1.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "paracetamol1000mg_day1" }, { "name": "paracetamol1000mg_day1, paracetamol_pre-treatment" } ] } ] }, "files": [ "https://pk-db.com/media/data/Bannwarth2001.pdf", "https://pk-db.com/media/data/Bannwarth2001_Tab1.png", "https://pk-db.com/media/data/Bannwarth2001_Fig1.png", "https://pk-db.com/media/data/Bannwarth2001.xlsx", "https://pk-db.com/media/data/.Bannwarth2001_Tab1.tsv", "https://pk-db.com/media/data/.Bannwarth2001_Fig1.tsv" ] }, { "sid": "PKDB00165", "name": "Prescott1973", "date": "2019-07-29", "reference": "4788034", "creator": "jbrandhorst", "curators": [ { "rating": 2.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "descriptions": [ "Thirty females and 11 males aged 16-72 years (mean 32 years) with admission plasma paracetamol concentrations exceeding 30, ug/ml after overdosage were studied." ], "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {}, {}, {} ] }, { "characteristica": [ {} ] }, {}, {}, {}, {}, {}, {}, {}, {}, {}, { "characteristica": [ {} ], "comments": [ [ "jbrandhorst", "renal failure" ] ] } ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Prescott1973_TabA.tsv", "characteristica": [ {}, {}, {}, {}, {} ] } ] }, "interventionset": { "interventions": [ { "comments": [ [ "jbrandhorst", "overdosed, plasma paracetamol concentrations exceeding 30 microg/ml after overdosage" ] ] } ] }, "outputset": { "comments": [ [ "jbrandhorst", "With the female subjects, study days were not standardised to any particular phase of the menstrual cycle. Of the control group females four were studied in the follicular phase and four in the luteal phase, while all OCS users were studied between days 5 and 22 of the pill cycle." ] ], "outputs": [ {}, {}, {}, {}, {}, { "source": "https://pk-db.com/media/data/.Prescott1973_Tab3.tsv", "image": "https://pk-db.com/media/data/Prescott1973_Tab3.png" }, { "source": "https://pk-db.com/media/data/.Prescott1973_Fig1.tsv", "image": "https://pk-db.com/media/data/Prescott1973_Fig1.png" }, { "source": "https://pk-db.com/media/data/.Prescott1973_Fig3.tsv", "image": "https://pk-db.com/media/data/Prescott1973_Fig3.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "subset Fig3: no liver damage_apapcys+apapglu" }, { "name": "apapcys+apapglu_subset Fig1: liver damage" }, { "name": "subset Fig3: no liver damage_paracetamol" }, { "name": "paracetamol_subset Fig1: liver damage" }, { "name": "subset Fig3: liver damage_paracetamol" }, { "name": "subset Fig3: liver damage_apapcys+apapglu" }, { "name": "apapcys+apapglu_subset Fig1: no liver damage" }, { "name": "paracetamol_subset Fig1: no liver damage" } ] } ] }, "files": [ "https://pk-db.com/media/data/.Prescott1973_Tab2.tsv", "https://pk-db.com/media/data/.Prescott1973_TabA.tsv", "https://pk-db.com/media/data/Prescott1973.xlsx", "https://pk-db.com/media/data/.Prescott1973_Fig1.tsv", "https://pk-db.com/media/data/Prescott1973.pdf", "https://pk-db.com/media/data/Prescott1973_Tab1.png", "https://pk-db.com/media/data/Prescott1973_Fig3.png", "https://pk-db.com/media/data/Prescott1973_Tab4.png", "https://pk-db.com/media/data/.Prescott1973_Fig3.tsv", "https://pk-db.com/media/data/.Prescott1973_Tab3.tsv", "https://pk-db.com/media/data/Prescott1973_Tab2.png", "https://pk-db.com/media/data/.Prescott1973_Tab1.tsv", "https://pk-db.com/media/data/Prescott1973_Fig1.png", "https://pk-db.com/media/data/Prescott1973_Fig2.png", "https://pk-db.com/media/data/Prescott1973_Tab3.png" ] }, { "sid": "PKDB00265", "name": "Hall1976", "date": "2019-11-09", "reference": "1264935", "creator": "jbrandhorst", "curators": [ { "rating": 3.0, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.5, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {} ], "descriptions": [ "The studies were carried out on six healthy male volunteers. One was taking long-term phenobarbitone and phenytoin, but the others were not on any drugs. All participants fasted 12 hr before each experiment and the same subjects were used throughout so that each subject acted as his own control." ] }, {} ], "comments": [ [ "jbrandhorst", "One was taking long-term phenobarbitone and phenytoin, but the others were not on any drugs." ] ] }, "individualset": { "individuals": [ { "source": "https://pk-db.com/media/data/.Hall1976_TabA.tsv" } ] }, "interventionset": { "interventions": [ { "descriptions": [ "Each subject ingested 40 ml absolute alcohol made up to 200 ml with water and orange cordial.", "ethanol (redistilled)" ] }, { "descriptions": [ "All subjects ingested 40 mg/kg paracetamol.", "Paracetamol (Panadol, Winthrop; 500 mg tablets)" ] }, { "descriptions": [ "The experiment was subsequently repeated following the ingestion of DMI 90 min before alcohol. Two doses of DMI were used: 75 mg in six/six subjects and 25 mg in five/six subjects.", "Desmethylimipramine (Pertofran, Geigy; 25 mg tablets)." ] } ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Hall1976_Fig2.tsv", "image": "https://pk-db.com/media/data/Hall1976_Fig2.png" }, { "source": "https://pk-db.com/media/data/.Hall1976_Fig1.tsv", "image": "https://pk-db.com/media/data/Hall1976_Fig1.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "paracetamol40mg_kg_po" }, { "name": "paracetamol40mg_kg_po,DMI" }, { "name": "alcohol,DMI" }, { "name": "alcohol" } ] } ] }, "files": [ "https://pk-db.com/media/data/Hall1976.xlsx", "https://pk-db.com/media/data/.Hall1976_TabA.tsv", "https://pk-db.com/media/data/Hall1976_Fig1.png", "https://pk-db.com/media/data/Hall1976_Fig3.png", "https://pk-db.com/media/data/.Hall1976_Fig2.tsv", "https://pk-db.com/media/data/Hall1976_Fig2.png", "https://pk-db.com/media/data/Hall1976.pdf", "https://pk-db.com/media/data/.Hall1976_Fig1.tsv" ] }, { "sid": "PKDB00152", "name": "SevillaTirado2003", "date": "2019-07-28", "reference": "14571283", "creator": "jbrandhorst", "curators": [ { "rating": 3.2, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.0, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "descriptions": [ "Bioavailability of Two New Formulations of Paracetamol, Compared With Three Marketed Formulations, in Healthy Volunteers" ], "licence": "closed", "access": "public", "groupset": { "descriptions": [ "Paracetamol was permitted up to 72 h prior to the trial, but could not be used as concomitant medication.", "Twelve healthy volunteers were included: 8 males and 4 females aged 29 ± 9.7 years. Concomitant medication was not permitted for 14 days prior to or during the trial. Paracetamol was permitted up to 72 h prior to the trial, but could not be used as concomitant medication." ], "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {}, {} ] } ] }, "individualset": {}, "interventionset": { "descriptions": [ "A: 2 x 500 mg paracetamol tablets (Laboratorios Belmac S.A)", "B: 1 x 1000 mg paracetamol powder sachets (Laboratorios Belmac, S.A.)", "C: 2 x 500 mg paracetamol film-coated tablets (Panadol®, SmithKline Beecham)", "D: 2 x 500 mg paracetamol tablets (Tylenol®, McNeil)", "E: 1 x 1000 mg effervescent paracetamol tablets (Efferalgan®, UPSA)." ], "interventions": [ { "comments": [ [ "jbrandhorst", "paracetamol1000mg_tablets" ] ] }, { "comments": [ [ "jbrandhorst", "paracetamol1000mg_powder" ] ] }, { "comments": [ [ "jbrandhorst", "Panadol, SmithKline Beecham" ] ] }, { "comments": [ [ "jbrandhorst", "Tylenol, McNeil" ] ] }, { "comments": [ [ "jbrandhorst", "Efferalgan, UPSA" ] ] } ], "comments": [ [ "jbrandhorst", "The five formulations were given to each volunteer in random order, separated by a washout period of at least 3 days." ] ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.SevillaTirado2003_Tab1.tsv" }, { "source": "https://pk-db.com/media/data/.SevillaTirado2003_Tab2.tsv" }, { "source": "https://pk-db.com/media/data/.SevillaTirado2003_Tab3.tsv" }, { "source": "https://pk-db.com/media/data/.SevillaTirado2003_Fig1.tsv", "image": "https://pk-db.com/media/data/SevillaTirado2003_Fig1.png" } ] }, "dataset": { "data": [ { "name": "AutoGenerate", "data_type": "timecourse", "subsets": [ { "name": "B" }, { "name": "C" }, { "name": "D" }, { "name": "E" }, { "name": "A" } ] } ] }, "files": [ "https://pk-db.com/media/data/SevillaTirado2003_Tab2.png", "https://pk-db.com/media/data/SevillaTirado2003.xlsx", "https://pk-db.com/media/data/.SevillaTirado2003_Tab1.tsv", "https://pk-db.com/media/data/.SevillaTirado2003_Tab2.tsv", "https://pk-db.com/media/data/SevillaTirado2003_Tab1.png", "https://pk-db.com/media/data/.SevillaTirado2003_Tab3.tsv", "https://pk-db.com/media/data/SevillaTirado2003.pdf", "https://pk-db.com/media/data/SevillaTirado2003_Tab3.png", "https://pk-db.com/media/data/.SevillaTirado2003_Fig1.tsv", "https://pk-db.com/media/data/SevillaTirado2003_Fig1.png" ] }, { "sid": "PKDB00262", "name": "Brodie1980", "date": "2019-11-08", "reference": "7397068", "creator": "jbrandhorst", "curators": [ { "rating": 2.5, "first_name": "Matthias", "last_name": "König", "pk": "84635ae4-d94f-46a1-a644-c6a91aeadc2a" }, { "rating": 0.5, "first_name": "Janosch", "last_name": "Brandhorst", "pk": "b8439e61-8aca-404d-bbed-a14c78da9d80" } ], "licence": "closed", "access": "public", "groupset": { "groups": [ { "characteristica": [ {}, {}, {}, {}, {}, {}, {} ] }, { "characteristica": [ {}, {}, {}, {}, {}, {}, {}, {} ], "descriptions": [ "Nine white vegetarians (six males, three females; 23-40 years) agreed to participate. Seven were lactovegetarians and two were vegans. They had been vegetarians for a mean of 5.1 years (0.5-14 years). None had any clinical evidence of hepatic, haematological or renal disease and baseline haemoglobin, urea and electrolytes and liver function tests were all normal. None smoked cigarettes or were on regular medication." ] }, {}, {}, { "characteristica": [ {}, {} ] } ], "comments": [ [ "jbrandhorst", "very strange group setup, in part published elsewhere (Dollory1979)" ], [ "jbrandhorst", "Seven were lactovegetarians and two were vegans. They had been vegetarians for a mean of 5.1 years (0.5-14 years)." ] ] }, "interventionset": { "descriptions": [ "The volunteers were studied on two occasions. On the first, antipyrine 600 mg and paracetamol 1.5 g were taken together and on the second, phenacetin 900 mg was ingested, both following an overnight fast." ], "interventions": [ {}, {}, {} ] }, "outputset": { "outputs": [ { "source": "https://pk-db.com/media/data/.Brodie1980_Tab1.tsv", "image": "https://pk-db.com/media/data/Brodie1980_Tab1.png" } ] }, "dataset": {}, "files": [ "https://pk-db.com/media/data/Brodie1980_Tab1.png", "https://pk-db.com/media/data/Brodie1980.pdf", "https://pk-db.com/media/data/Brodie1980.xlsx", "https://pk-db.com/media/data/.Brodie1980_Tab1.tsv" ] } ] } }
